Prosecution Insights
Last updated: November 04, 2026
Application No. 18/727,093

MODIFIED LOW MOLECULAR WEIGHT GLUTENIN SUBUNIT AND USES THEREOF

Non-Final OA §112
Filed
Jul 07, 2024
Priority
Jan 10, 2022 — provisional 63/297,803 +1 more
Examiner
LOUNTOS, GEORGE THEMISTOCLIS
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ukko Inc.
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
4 granted / 7 resolved
-2.9% vs TC avg
Strong +60% interview lift
Without
With
+60.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
44 currently pending
Career history
44
Total Applications
across all art units

Statute-Specific Performance

§101
5.4%
-34.6% vs TC avg
§103
27.9%
-12.1% vs TC avg
§102
24.5%
-15.5% vs TC avg
§112
37.4%
-2.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 7 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims Status Claims 2-4, 6-8, 11, 13, 15-17, 20 and 22-28 are canceled. Claims 1, 5 and 19 are amended. Claims 1, 5, 9-10, 12, 14, 18-19, 21 and 29-39 are pending. Election/Restrictions Applicant’s election without traverse of Group 1 (claims 1, 5, 9-10, 12, 14, 18-19, 21 and 29-39 in the reply filed on 09/29/2026 is acknowledged. Applicant has canceled claims 2-4, 8, and 20. Applicant has canceled claims drawn to Groups 2 (claim 16) and 3 (claims 23-27). Applicant’s election without traverse of: Species Group 1: SEQ ID NO: 11 Species Group 2: Applicant has canceled claim 8. Species Group 3: Applicant has canceled claim 24 Species Group 4: Applicant has canceled claim 26. Species Group 5: Applicant has canceled claim 27 in the reply filed on 09/29/2026 is acknowledged. Information Disclosure Statement The information disclosure statements (IDS) submitted on 10/10/2024 and 09/29/2026 are acknowledged. The submission is in compliance with the provision of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered. Drawings Specific deficiency – Nucleotide and/or amino acid sequences appearing in the drawings are not identified by sequence identifiers in accordance with 37 CFR 1.821(d). Sequence identifiers for nucleotide and/or amino acid sequences must appear either in the drawings or in the Brief Description of the Drawings. Required response – Applicant must provide: Replacement and annotated drawings in accordance with 37 CFR 1.121(d) inserting the required sequence identifiers; (see Fig.1A, Fig. 1B, Fig. 1C, Applicant should clarify that the number in parenthesis is a SEQ ID NO.) AND/OR A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3) and 1.125 inserting the required sequence identifiers into the Brief Description of the Drawings, consisting of: A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); A copy of the amended specification without markings (clean version); and A statement that the substitute specification contains no new matter. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (see Specification, paragraph 0100). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 5, 9-10, 12, 14, 18-19, 21, and 29-39 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. With regards to claim 1 (and claims 5, 9-10, 12, 14, 18-19, 21, and 29-39 dependent on), the claims recite “a de-epitoped low molecular-weight glutenin subunits (LMW-GS)”. It is unclear what the meaning of de-epitoped is as the specification does not provide a definition for the term de-epitoped. In the interest of advancing prosecution, the Examiner is interpreting de-epitoped as mutagenesis or deletion of an immunogenic sequence. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 5, 9-10, 12, 14, 18-19, 21, and 29-39 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 (and claims 5, 9-10, 12, 14, 18-19, 21, and 29-39 dependent on) is directed to all possible de-epitoped low molecular weight glutenin subunits (LMW-GS) comprising an amino acid sequence of one of SEQ ID NO: 11, 12, 14, 15, 17, 18, 19, 20, 176, 177, 178, or 179 . The specification, however, only provides a working example of a WT LMW-GS polypeptides lacking an immunogenic epitope comprising the sequence set forth in any of SEQ ID NO: 88, 112, 162, 164, 166, and 168-173 (see specification paragraph 0033). The specification also only provides working examples of WT T-cell epitopes present in a LMW-GS comprising an amino acid sequence set forth in any of SEQ ID NO: 1-9, 21-48, and 50-64 (see specification paragraph 0032). The specification also only provides a working example of wheat (Triticum aestivum L) (see specification paragraph 0004). There is no disclosure of any particular structure to function/activity relationship in the disclosed species. Regarding the level of skill and knowledge in the art of immunology, the reference of Sollid et al. (Immunogenetics, Vol. 64, pg. 455-460; published 2012) teaches that celiac disease is caused by an abnormal T-cell response to gluten proteins of wheat, barley and rye. Sollid teaches that over the last few years, a number of gluten T-cell epitopes restricted by celiac disease associated HLA-DQ molecules have been characterized (see abstract, pg. 455). Sollid teaches that gluten is now increasingly used as a term to denote proline and glutamine rich proteins of wheat, barley, rye, and oat. In wheat, gluten consists of the gliadin and glutenin subcomponents. Sollid teaches that the glutenin proteins can be subdivided into high molecular weight and low molecular weight (LMW) subunits (see pg. 456). Sollid teaches that in a single wheat variety there exists up to several hundred different gluten proteins, many which only differ by a few amino acids (see pg. 456). Sollid teaches that given the heterogeneity of wheat gluten proteins, it is no surprise that many distinct glutenin derived T-cell epitopes exists (see pg. 456 and Table 2). The reference of Mameri et al. (Journal of Agricultural and Food Chemistry, Vol. 60, pg. 7538-7547; published 2012) teaches that wheat-derived products are responsible for adverse reactions such as intolerances and allergies (see Introduction, pg. 7538). Mameri teaches that wheat proteins are classified into their solubility profiles and the water insoluble fraction which is the main component of gluten is composed of prolamins, so called because of their high glutamine and proline residues. Wheat prolamins are further divided into gliadins and glutenin subunits. The glutenin subunits are further divided into two classes, the high molecular weight glutenin submits and the low molecular weight subunits (LMW-GS) (see pg. 7538). Mameri teaches that many wheat seed proteins, LMW-GSs were found to exhibit IgE-binding activities in allergies (see pg. 7540). Mameri also teaches that two LMW-GSs known as P73 and B16 were cloned and characterized to identify IgE-binding epitopes (see Materials and Methods, pg. 7540). Mameri teaches that many linear epitopes were found using Pepscan and that 13 new linear epitopes not found in previous study were identified (see pg. 7544). The reference of Shewry (Journal of Cereal Science, Vol. 67, pg. 12-21; published 2016) teaches that currently thirty-one, nine amino acid peptide sequences in the prolamins of wheat and related species have been identified as being coeliac toxic: these are often referred to as coeliac “epitopes”. However, mapping is incomplete and the number of distinct epitopes is a matter of on going discussion (see section 2.2 identification of coeliac epitopes, pg. 14). Shewry further teaches a summary of major cultivated and wild-species of wheat such as T. monococum var. monococum, T. turgidum var. dicoccum, T. turgidum var. durum, T.aestivum var. aestivum, T. aestivum var. spelta, T. tauschii, T. Urartu, T. monocucum var. boeticum, and T. trugidum var. dicoccoides (see Table. 1, pg. 15). Given the lack of additional representative species as encompassed by the claims, Applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise, and exact terms that a skilled artisan would recognize Applicants were in possession of the claimed invention. Closest Prior Art The reference of Orfan et al. (WO 2020/008412; published January 09, 2020) teaches a method for de-epitoping a wheat polypeptide, the method comprising mutating one or more amino acid residues of a celiac-associated epitope on the wheat polypeptide to generate a de-epitoped polypeptide (see claim 2, pg. 51). Ofran teaches that the polypeptide is a glutenin (see claim 5) and in one embodiment the glutenin is a low-molecular weight glutenin (see lines 15-17, pg. 13). Ofran does not teach a de-epitoped low molecular weight glutenin subunits comprising an amino acid sequence of one of SEQ ID NOs: 11, 12, 14, 15, 17, 18, 19, 20, 176, 177, 178, or 179. The reference of UniProt Accession No. A0A3N2PN74 (first entry February 13, 2019) has a 100% identical match to sequence ID NO: 11, but does not anticipate claim 1 as a person of ordinary skill in the art would not find it obvious as to how to apply the sequence. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GEORGE T LOUNTOS whose telephone number is (571)272-0502. The examiner can normally be reached Monday-Friday 8:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached at 408-918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GEORGE THEMISTOCLIS LOUNTOS/ Examiner, Art Unit 1652 /ROBERT B MONDESI/ Supervisory Patent Examiner, Art Unit 1652
Read full office action

Prosecution Timeline

Jul 07, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781287
INSTANT NUCLEIC ACID TEST METHOD AND TEST KIT FOR PATHOGENIC MUTANTS
3y 10m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
99%
With Interview (+60.0%)
3y 5m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 7 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month